By Diagnostics World Staff
July 25, 2017 | Elena Grigorenko, VP of research and development at Diatherix, talked with Edel O’Regan about the upcoming Next Generation Dx Summit.
Grigorenko and O’Regan briefly discuss what happens when science outpaces reimbursement, how to develop and validate a genetic drug resistance panel, and whether the industry is ready for next-generation sequencing.
“I am specifically interested to hear about practical experience of utilization of next generation sequencing in routine diagnostic practice for pathogen detection,” Grigorenko says of her expectations for the conference. “I do believe that existing molecular diagnostics such as multiplex PCR tests will be replaced in the future by viral or bacterial targeted sequencing. However this is not ready yet, because the complex sample prep work load, long turn around time, lack of clear regulatory guidelines for validation of such complexity tests presents a significant hurdle for adoption of next gen sequencing in a clinical microbiological laboratory.”
Listen to the podcast